ImmunityBio (ImmunityBio) FCF Margin % : -88,651.80% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ImmunityBio's Free Cash Flow for the three months ended in Dec. 2023 was $-123.23 Mil. ImmunityBio's Revenue for the three months ended in Dec. 2023 was $0.14 Mil. Therefore, ImmunityBio's FCF Margin % for the quarter that ended in Dec. 2023 was -88,651.80%.

As of today, ImmunityBio's current FCF Yield % is -6.62%.

The historical rank and industry rank for ImmunityBio's FCF Margin % or its related term are showing as below:

IBRX' s FCF Margin % Range Over the Past 10 Years
Min: -182041.67 Med: -32974.52 Max: -7102.45
Current: -63881.19

During the past 5 years, the highest FCF Margin % of ImmunityBio was -7102.45%. The lowest was -182041.67%. And the median was -32974.52%.

IBRX's FCF Margin % is ranked worse than
97.3% of 1037 companies
in the Biotechnology industry
Industry Median: -148.24 vs IBRX: -63881.19

ImmunityBio FCF Margin % Historical Data

The historical data trend for ImmunityBio's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio FCF Margin % Chart

ImmunityBio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-7,102.45

-28,660.00

-32,974.52

-182,041.67

-63,881.19

ImmunityBio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial												-150,216.44	-25,760.56	-215,363.41	-113,509.76	-88,651.80

Competitive Comparison of ImmunityBio's FCF Margin %

For the Biotechnology subindustry, ImmunityBio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunityBio's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunityBio's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ImmunityBio's FCF Margin % falls into.

ImmunityBio FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ImmunityBio's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-397.341	/	0.622
	=	-63,881.19 %

ImmunityBio's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-123.226	/	0.139
	=	-88,651.80 %

ImmunityBio FCF Margin % Related Terms

Thank you for viewing the detailed overview of ImmunityBio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio (ImmunityBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

26CA:Germany

Address

3530 John Hopkins Court, San Diego, CA, USA, 92121

Website

https://www.immunitybio.com

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

Executives

Patrick Soon-shiong	director, 10 percent owner, officer: See remarks	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc	10 percent owner	10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk	director	C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark	director	C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer	officer: Chief Accounting Officer	4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock	officer: Chief Executive Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs	officer: Chief Financial Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll	director